Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.44 |
| ▸ | GSK3A | P49840 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | GAK | O14976 | 3/20 | 0.38 |
| ▸ | STK16 | O75716 | 3/20 | 0.38 |
| ▸ | BMP2K | Q9NSY1 | 3/20 | 0.38 |
| ▸ | CDKL2 | Q92772 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675958 | 0.81 | GSK3B (0.43) | GSK3BGSK3ACYP1A2AAK1CDK2 | |
| SCHEMBL16675964 | 0.78 | GSK3B (0.49) | GSK3BGSK3ACYP1A2AAK1CDK2 | |
| SCHEMBL19976744 | 0.78 | GSK3B (0.45) | GSK3BGSK3AMAPK1CYP1A2AAK1 | |
| SCHEMBL16675927 | 0.78 | RET (0.37) | GSK3BCDK2 | |
| SCHEMBL16675963 | 0.78 | GSK3B (0.48) | GSK3BGSK3ACYP1A2AAK1CDK2 | |
| SCHEMBL16752833 | 0.77 | HDAC6 (0.45) | GSK3BMAPK1CYP1A2HDAC6 | |
| SCHEMBL19976886 | 0.77 | GSK3B (0.43) | GSK3BGSK3AMAPK1CYP1A2HDAC6 | |
| SCHEMBL16752836 | 0.77 | HDAC6 (0.45) | GSK3BMAPK1CYP1A2HDAC6 | |
| SCHEMBL16769264 | 0.77 | HDAC6 (0.45) | GSK3BMAPK1CYP1A2HDAC6 | |
| SCHEMBL16682078 | 0.76 | CACNA1I (0.35) | GSK3BCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | GSK3B 4407/4885GSK3A 4056/4885MAPK1 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.